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Abstract
Pituitary adenomas (PA), or pituitary neuroendocrine tumors (PitNETs), represent 15% of all central nervous system tumors. Classic
description of PitNETs solely by hormonal classification has given way to key transcription factors that play a role in the pathology of
PitNETs including steroidogenic factor-1 (SF-1), t-box pituitary transcription factor (TPIT), and pituitary transcription factor 1 (PIT-1).
Germline mutations in various familial PitNETs are discussed including those in familial isolated pituitary adenoma (FIPA), multiple
endocrine neoplasia (MEN), neurofibromatosis 1 (NF1), and Carney complex. Recent advances in next generation sequencing have
improved insight into the pathogenesis of PitNETs. A review of key studies in evaluating the genomic analysis of PitNETs was performed.
Chromosomal mutations, whole exome sequencing, microRNA genomics, methylomics and transcriptomics were analyzed. Moreover,
the multiomic analysis of various genomic panels has helped to better understand PA classification.
Keywords: pituitary adenoma; molecular genetics; PitNET; genomics; SF-1; TPIT; PIT-1

1. Introduction
Pituitary tumors represent nearly 15% of all central
nervous system (CNS) tumors and are mostly comprised of
pituitary neuroendocrine tumors (PitNETs), formerly called
pituitary adenomas in earlier World Health Organization
(WHO) classifications [1]. While most often benign, PitNETs can lead to a wide range of clinical symptoms through
hormone secretion or mass effect on critical structures. The
diagnosis and evaluation of PitNETs has evolved from the
original histological description, e.g., acidophil, basophil,
or chromophobe tumors as determined by hematoxylin and
eosin staining. Most recently, however, there has been a
concerted effort to develop a more personalized approach to
diagnosing PitNETs that relies on the genetic, transcription,
and protein biomarkers. In 2014, Raverot et al. [2] demonstrated the prognostic value of using genetic markers in the
identification of tumors by proposing a novel clinicopathological classification that consisted of tumor size, hormonal
immunochemistry, invasiveness, and markers of proliferation. The proposed classification demonstrated high prognostic value in predicting post-operative outcomes. With
each successive iteration to the WHO classification, there
has been a pivot away from the nonspecific nomenclature
of “hormone-producing pituitary adenomas” and a shift towards the adenohypophyseal cell lineage designation of the
tumors. In 2017, the WHO published the 4th edition of
the classification of endocrine tumors and updated their diagnostic guidelines for PitNETs, introducing transcription
factors into the diagnostic criteria [3]. This has been further solidified in the 2021 WHO guidelines [4].

The advancement of next generation sequencing
genomics, including methylomics, transcriptomics, proteomics and even glycomics, have reinvigorated the discovery of disease pathogenesis. The integration of multiple platforms, termed multiomics, can be an effective way
to understand disease across different levels of gene regulation. Biomarkers can also be combined with imaging
and clinical assessment. Studying the multiomics of PitNETs has the tremendous potential of enhancing our understanding of the pathogenesis, invasiveness, recurrence, and
prognosis of these tumors. In this review paper, we provide
a detailed account of how multiomics is being utilized for
optimizing the diagnosis and treatment of PitNETs.

2. Incorporation of multiomics in 2017 WHO
classification of tumors of the pituitary gland
In 2017, WHO revised the classification of PitNETs
to better represent the clinical characteristics of these tumors. A new emphasis was placed on identifying lineagerestricted pituitary transcription factors to determine adenohypophysial cell lineages. Recent studies have revealed
that key transcription factors which drive normal adenohypophysial cell differentiation also play key roles in PitNET cytodifferentiation and hormone production [5]. The
three main adenohypophysial cell lineages and their correlated transcription factors are (Fig. 1): (1) gonadotrophs
driven by expression of steroidogenic factor-1 (SF-1), (2)
corticotrophs driven by t-box pituitary transcription factor
(TBX19 or TPIT), and (3) somatotrophs, thyrotrophs, lactotrophs, and mammosomatotrophs driven by pituitary tran-
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scription factor 1 (PIT-1; also known as POU1F1) [6]. Null
cell tumors and plurihormonal tumors are considered separately: null cell tumors do not express any transcription
factors, immunomarkers, or hormones, whereas plurihormonal tumors produce multiple hormones and are usually
associated with PIT-1.

Fig. 1. Classification of pituitary tumors by transcription factors and hormonal staining. ACTH, adrenocorticotropic hormone; FSHβ, follicle-stimulating hormone; GH, growth hormone; PIT-1, pituitary transcription factor 1; PRL, prolactin; SF-1,
steroidogenic factor 1; TPIT, t-box pituitary transcription factor;
TSHβ, thyroid stimulating hormone β.

The use of transcription factors is more reliable than
prior methods that relied on microscopic morphology, immunohistochemistry against hormones, in situ hybridization, reverse hemolytic plaque assays, and electron microscopy [6]. Transcription factor identification is especially useful in tumors with minimal immunopositivity such as silent corticotrophs, somatotrophs, plurihormonal and immunonegative tumors [5]. Approximately
70–80% of non-functional adenomas show staining for
gonadotrophins, termed silent gonadotrophin adenomas
(SGA) which overlap histologically with null cell adenomas
that are more clinically aggressive [7]. Various transcription factors, including SF-1, PIT-1, and TPIT have been
able to distinguish SGA from null cell adenomas (NCA).
Importantly, while transcriptomics has improved the specificity of adenoma diagnosis, it is only partially descriptive
of the tumor and should be used in conjunction with classi2

cal methods of diagnosis such as hormone expression [5,8].
The 2017 WHO reclassification also abandoned the
term “atypical adenoma”, which was previously defined by
mitotic index >3%, Ki-67 expression >3%, and positive
p53 staining, as its prognostic value was inconsistent [3].
Instead, the authors suggest considering the rate of growth,
extent of invasion, and Ki-67 expression to define the aggressiveness of a tumor [3,6].
Several specific PitNET tumors have been identified
as especially high-risk. One type, silent corticotroph adenomas are TPIT positive, often large, and tend to invade
the cavernous sinus [9,10]. Given their propensity towards
more frequent and earlier recurrences, they should be monitored closely postoperatively. Notably, they often exhibit
inconsistent Ki-67 and p53 levels and may rarely transform into carcinomas [11]. Crooke’s cell adenomas are another aggressive subtype of the corticotroph lineage that require close monitoring following resection given their exceptional tendency to recur [12]. Sparsely granulated somatotoph adenomas are an aggressive subtype of PitNETs
which can be identified by their PIT-1 positivity and characteristic sparse granulation on histology [13]. Finally,
plurihormonal PIT-1-positive adenomas, formerly known
as silent adenoma type III, are large, monomorphous, invasive tumors with very high rates of recurrence [10,14].
The 2021 WHO classification of central nervous system (CNS) follows the 2017 WHO classification, grouping
PitNETs by adenohypophyseal cell lineage and expression
of pituitary hormones and transcription factors [4]. Both
the 2017 and 2021 WHO classifications also recognize a
new entity, the pituitary blastoma, which is a rare embryonal neoplasm of infancy composed of primitive blastemal
cells, neuroendocrine cells, and Rathke epithelium. Pituitary blastomas are usually seen as part of the DICER1 syndrome and most commonly produce ACTH followed by GH
[4].
While the 2017 WHO classification transitioned towards the use of transcription factor use for tumor identification, there has also been a rapidly growing body of literature on the multiomic dysregulations that contribute to
the pathogenesis of nonfunctioning, functioning, and familial pituitary adenomas. For each type of tumor, we discuss
the genomics, epigenetic, exomic, transcriptomic, and proteomic dysregulations as well as provide their clinical correlates.

3. Pathogenesis of nonfunctioning pituitary
neuroendocrine tumors
3.1 Dysregulated signaling pathways in non-functioning
PitNETs
Nonfunctioning pituitary adenomas (NF-PitNETs)
are typically benign, characterized by their absence of
hormonal overproduction, and show specific molecular
changes that are hallmarks to their pathogenesis. Using immunohistochemical testing, NF-PitNETs are divided

into null cell adenomas and clinically silent gonadotrophs.
Based on the 2017 WHO classification, null cell adenomas are defined as a pituitary adenomas without immunohistochemical evidence of cell-type-specific differentiation
when using pituitary transcription factors and adenohypophyseal hormones. Silent gonadotrophs are discussed
separately in section 4.2.
Two major signaling pathways at the genomic
level contribute to the pathogenesis of nonfunctioning pituitary adenomas (Fig. 2): phosphoinositide 3kinase (PI3K)/AKT and mitogen-activated protein kinase
(MAPK). The PI3K/AKT signaling pathway promotes
pathogenesis when there is dysregulation of the mammalian
target of rapamycin (mTOR), Wnt, nuclear factor kappa
B (NF-κB), and pro-apoptotic pathways [15,16]. Aberrant AKT and mTOR activity is often implicated across
the spectrum of malignancies. Long et al. [17] demonstrated that AKT1, AKT2, and AKT3 are upregulated in
NF-PitNETs relative to normal pituitary tissue. Upregulation of SHIP, GRB2 Associated Binding Protein 1/2
(GAB1/2), SHC, Son of Sevenless (SOS), AKT, IkappaB
Kinase (IKK), NF-κB, MEK1/2, ERK1/2, mTOR, 4E-BP1,
glycogen synthase kinase 3 Beta (GSK3), and β-catenin
along with downregulation of phosphoinositide 3-kinases
(PI3K) p85, heat shock protein 90 (HSP90), and BAD were
seen in patients with NF-PA, which are all downstream of
PI3K/AKT signaling. Dysregulation of AKT results in disturbances in the mTORC1 signaling, Wnt pathway, NFκB
signaling, and BAD pro-apoptotic activity. The mTOR
pathway is downstream to PI3K/AKT and can be contributory through upregulation of the extracellular signalregulated kinase 1/2 (ERK1/2), AKT, ribosomal s6 kinase
(RSK), mTOR, PRAS40, RPTOR Independent Companion
Of MTOR Complex 2 (RICTOR), 4EBP, ribosomal protein
S6 (RPS6) and 40S ribosome, while downregulation of protein kinase C (PKC), PKCa, and p-AEBP.
The MAPK signaling can be dysregulated in NFPitNETs through alterations in the ERK1/2, JNK, p38 and
ERK5 pathways. Through pathway network analysis, Long
et al. [17] demonstrated that ERK/MAPK pathways were
significantly activated in NF-PA development. It is well
reported that ERK/MAPK can regulate proliferation apoptosis, and stress responses. ERK1/2 is upregulated through
the cascade reactions in the RAS-Raf-MEK-ERK1/2 activation fashion. Phosphorylation at Ser446 or Ser447 in BRaf are significantly increased in NF-PitNETs, in turn causing abnormal constitutive activation of the ERK/MAPK
pathway. The two final important stress-activated cascades
are p38 and JNK; they share synergistic functionality and
both play important roles in inflammatory responses and
controlling apoptosis. Both p38 and JNK pathways are involved in NF-PitNETs.

3.2 DNA hypermethylation in non-functioning PitNETs
Genome-wide methylation assays of functioning vs.
nonfunctioning adenomas revealed that NF-PitNETs, in
general, are defined by a higher frequency of gene hypermethylation [18]. Assessing β-values, with 0 being unmethylated and 1 being totally methylated, between normal pituitary sections and tumor sections reveal more methylation
on average in NF-PitNETs. The researchers were able to
identify the aberrantly methylated CpG loci, and upon further analysis of the regions of interest they found significantly higher levels of methylation occurring on select promoters stratifin (SFN), signal transducer and activator of
transcription 5A (STAT5A), fibroblast growth factor receptor 2 (FGFR2), dual specificity phosphatase 1 (DUSP1),
and protein tyrosine phosphatase receptor type E (PTPRE).
These promoters have not been extensively studied in the
context of pituitary tumors, but the epigenetic silencing of
SFN which encodes for the 14-3-3 protein, a known tumor suppressor, is similar to effects in other tumors such
as gynecological malignancies. STAT5A expression is inversely correlated with promoter DNA methylation and
downregulated in NF-PitNETs. Methylation profiles can
also elucidate which downstream pathways are driven by
the changes: Kober et al. [19] found that Wnt signaling,
p53 signaling, and PI3K/AKT signaling were significantly
more enriched in NF-PitNETs compared to normal pituitary
sections.
3.3 Transcriptomics in non-functioning PitNETs
Principal component analysis (PCA) of the transcriptomics of non-functional compared to functional PitNETs revealed that pituitary tumors clustered according
to the transcription factor responsible for cytodifferentiation of the pituitary gland. Pituitary tumors, were
seen to cluster among 3 subtypes depending on driving transcription factors [20]. Clinically follicle stimulating hormone (FSH)/leutinizing hormone (LH)-PitNETs
and NCAs were driven by SF-1, while adrenocorticotropic
hormone (ACTH)-PitNETs, and silent corticotroph PitNETs were driven by TPIT, and thyroid-stimulating hormone (TSH), prolactin (PRL)-, and growth hormone (GH)PitNETs were driven by PIT-1. Pathway enrichment analysis found several NF-PitNETs demonstrated significant
alterations of genes involved in metabolism resulting in
higher upregulation of calcium signaling pathways compared with functional adenomas. Moreover, the transcriptome of NF-PitNETs showing alterations in calcium-related
genes implicated a wide-range of disrupted signaling pathways. Distinctly, ACTH-PitNETs showed enrichment of
renin-angiotensin system regulation and TSH-/PRL-/GHPitNETs showed clustering of fatty acid metabolism genes.
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Fig. 2. Genetic factors and molecular changes involved in pituitary adenoma pathogenesis. Various genetic factors and molecular
changes that play a role in pituitary tumor pathogenesis. AIP, aryl hydrocarbon receptor interacting protein; CABLES1, Cdk5 and Abl
Enzyme Substrate 1; DAPK, death-associated protein kinase; DNMT1, DNA methyltransferase 1; DRD2, dopamine receptor D2; FGFR2,
fibroblast growth factor receptor 2; GADD45γ, Growth arrest and DNA-damage-inducible protein 45γ; HGMA2, High Mobility Group
AT-Hook 2; HIF1, hypoxia inducible factor 1; MAGE-3, melanoma-associated antigen 3; MAPK, mitogen-activated protein kinase;
MEG3, maternally expressed gene 3; PAX7, paired box protein 7; PI3K, phosphoinositide 3-kinases; PIT-1, pituitary transcription factor
1; PRKAR1A, cAMP dependent protein kinase A (PKA) type I-α regulatory subunit (RIα); PTTG, securing; RPRM, reprimo; SDH,
succinate dehydrogenase; SFRP2, secreted frizzled related protein 2; SF-1, steroidogenic factor 1; SMARC4, SWI/SNF related, matrix
associated, actin dependent regulator of chromatin A4; TPIT, t-box pituitary transcription factor; USP8, ubiquitin specific peptidase 8;
VEGF, vascular endothelial growth factor; WIF1, wnt inhibitory factor 1.

4. Pathogenesis of functioning pituitary
adenomas
4.1 Overview of functional PitNET classification
Functioning PitNETs are divided into 5 main “troph”
subtypes (with respective hormone markers): lactotrophs
(PRL), somatotrophs (GH), thyrotrophs (TSH), corticotrophs (ACTH), gonadotrophs (FSH/LH). However,
there are multiple layers of genetic, transcriptomic, proteomic alterations that have redefined the PitNET landscape where single driver gene mutations have been unable
(Fig. 2). While 80% of PitNETs show some disruption to
the cell cycle, most tumors present with no observed genetic
changes [21]. However, somatic mutations that accelerate
tumorigenesis can be seen in up to 40% of PitNETs [22].
Neou et al. [23] evaluated 134 patients with a large
variety of functional tumor types with differing aggressiveness via multiomics, specifically assessing chromosomal alterations, miRNomics, methylomics and RNA transcriptomics. They demonstrated that the methylome of
PitNETs stratified the tumors into three groups, based on
4

collapsed CpGs and associated with secretion type: met1
correlated with somatotrophs, lactotrophs, and thyrotrophs;
met2 correlated with gonadotrophs; met3 correlated with
corticotrophs. They noted that PIT-1 mutations may drive
expression of tet methylcytosine dioxygenase 2 (TET2),
which encodes a demethylating enzyme where PIT-1 derived tumors demonstrate global hypomethylation.
With regards to assessing epigenetic activity Neou et
al. [23] investigated the viability of microRNAs (miRNA)
as a method for classification. MicroRNA are noncoding
RNAs responsible for gene expression/silencing through
RNA cleavage. PitNETs were divided into 4 groups
based on miRNA clusters and these groups separated PRL
(miR1), GH (miR2), ACTH (miR3), and FSH/LH tumors
(miR4).
Finally, investigating the transcriptome of PitNETs
by RNA sequencing produced arguably the most informative profile to date. To bypass the need for exome enrichment, researchers may opt for RNA sequencing (transcriptome sequencing), analyzing the RNA being tran-

scribed in a cell/tissue at that time. A benefit to high
throughput RNA sequencing is that it provides insight into
which genes are active and quantifies how much they are
transcribed, however it does not identify eventual downstream translated proteins. Using their 134 samples to
determine mRNA clusters, Neou and colleagues categorized the tumors into 6 distinct groups (t1–t6) that correlated with the WHO 2017 classification guidelines, with
a few notable discrepancies. Mixed GH-PRL PitNETs
were clustered together with somatotroph PitNETs (t6 cluster), implying that they are GH-predominant in origin.
USP8 wild-type corticotrophs (t1 cluster) appeared more
aggressive with greater sphenoid sinus invasion, which was
further supported by the transcriptome demonstrating increased epithelial-mesenchymal-transition (EMSA) signature. Overall, multifactor analysis that combined transcriptome classification with GNAS/USP8 mutation status better fit the molecular groups than the WHO 2017 histoprognostic classifications.
Neou et al. [23] performed whole exome, single
nucleotide polymorphisms (SNP), DNA methylation, microRNA profiling, and mRNA sequencing on 134 PitNETs.
Multifactor analysis provided a comprehensive and new
molecular classification for PitNETs that, in addition to
confirming the histological relevance of WHO 2017 classifications, provided an accurate pangenomic blueprint for
predicting a tumor’s aggressiveness and responsiveness to
treatment.

and postoperative diabetes insipidus (p = 0.028) than NCAs.
NCA subtypes were independently associated with tumor
recurrence (HR 3.64, 95% CI 1.07–12.30; p = 0.038), cavernous sinus invasion (HR 3.97, 95% CI 1.04–15.14; p =
0.043) and larger anteroposterior dimension of the tumor
(HR 2.23, 95% CI 1.09–4.59; p = 0.030).
Gonadotrophs can also present as part of a synchronous multiple PitNET lesion. In a study of 1055 PitNETs, 13 (1.23%) tumors had more than one cell lineage
[25]. Of the 13 tumors, 8 were gonadotrophs that co-existed
with one of the following tumors: lactrotroph, poorly differentiated PIT-1 tumor, or corticotroph.
Epigenetic dysregulation also significantly varies by
PitNET subtype and makes up an important part of PitNET
multiomics. In a study of 105 PitNETs, 35 (33.3%) were
SGAs and were found to have hypermethylation of estrogen receptor 1 (ESR1) and Ras Association Domain Family Member 1 (RASSF1) genes (p = 0.055 and p = 0.050,
respectively) [27]. Both ESR1 and RASSF1 are implicated
in cancer progression.
Further, a study by Principe et al. [28] discovered
that gonadotrophs have an increased number of CD68+
and CD163+ M2-like macrophages. Presence of M2-like
macrophages correlated well with increased gonadotroph
tumor invasion that is mediated by collagen degradation via
the matrix metalloproteinase-9 enzyme (MMP-9). M2-like
macrophages exert a protumor role in solid tumors, promoting aggressiveness, proliferation, and invasion.

4.2 Gonadotrophs

4.3 Corticotrophs

Gonadotrophs are a great example of the need for
genetic testing to determine the PitNET subtype. Gonadotrophs are commonly negative for FSH and LH but
can be reliably detected by their nuclear immunoreactivity for SF-1. Given the lack of hormone secretion, they
are often clinically silent and therefore act like nonfunctioning adenomas [24]. Among those that stained positive
for a pituitary hormone, FSH-positive tumors were significantly more common than LH-positive tumors. Despite being clinically silent, these tumors are distinct from null cell
tumors. In addition to SF-1 expression, these tumors show
variable expression of nuclear transcription factors including estrogen receptor α (Erα), and GATA2/3 [25]. When
comparing to NCAs, SGAs had lower MIB-1 levels (2.49
± 1.41%) than NCAs (3.43 ± 2.76%; p = 0.044). Further,
Hong et al. [26] showed that NCAs more commonly invade the cavernous sinus than gonadotroph adenomas (p
= 0.043), which led to a significant difference in extent of
gross total resection (p = 0.039). Gonadotrophs tend to be
indolent in nature. In a study for 1166 patients with pituitary adenomas, 12.8% (n = 149) were SGAs and 9.2% (n
= 107) were NCAs. NCAs were significantly more common in female patients than SGAs (61.7% vs 26.8%, p <
0.001). Gonadotrophs had a significantly lower recurrence
(p = 0.021), adjuvant radiation therapy usage (p = 0.002),

The second most commonly-identified somatic mutation, a gain-of-function Ubiquitin Specific Peptidase 8
(USP8) mutation, occurs in 30% of corticotroph tumors.
Song et al. [29] sequenced 125 adenomas and found recurring mutations of USP8 in corticotrophs. USP8 encodes
for a deubiquitinase enzyme that removes conjugated ubiquitin from epidermal growth factor receptor (EGFR), thus
preventing EGFR degradation. Gain-of-function mutations
in USP8 increase deubiquination of EGFR leading to excess
EGFR signaling as well as increased proopiomelanocortin
(POMC) levels. Cleavage of POMC leads to the ACTH
peptide hormone. Clinically, USP8-positive tumors are
smaller, more frequently found in females, produce more
ACTH, and have better outcomes when compared to USP8negative corticotrophs. USP8 wild-type PitNETs appeared
more aggressive when compared to USP8-mutated PitNETs
(p = 0.018) with more common sphenoid sinus invasion (p
= 0.007). However, in a study by Albani et al. [30], USP8mutated corticotroph tumors were diagnosed at a younger
age (p = 0.028), had higher preoperative 24-hour urinaryfree cortisol levels (p = 0.045), and had a higher recurrence rate (p = 0.026) at the 10-year follow-up than the
USP8-wild type tumors. Further, the elevated invasiveness
of PitNETs with wild-type USP8 was corroborated by the
increased the epithelial-mesenchymal-transition signature
5

in the transcriptome signature of corticotrophs, a genetic
marker of tumor aggressiveness. Interestingly, USP8 status
did not affect cavernous sinus invasion or MIB1/Ki67 index. Furthermore, somatostatin receptor 5 (SSTR5) expression is increased in USP8-mutated corticotroph PitNETs.
The presence of USP8 mutation may reflect more favorable
response to somatostatin receptor ligands (e.g., paserotide)
and EGFR-directed therapies (e.g., geftinib).
Epigenetic alterations in DNA methylation also play a
role in corticotroph PitNET tumorigenesis. Salomon et al.
[31] reported that DNA hypomethylation was seen in only
some of the PitNET subtypes; more specifically, POMC
hypomethylation was noted in ACTH-secreting tumors. It
is worth noting that in corticotroph PitNETs, expression of
SSTR5 was also higher in USP8-mutated tumors compared
with USP8-wild type tumors.
4.4 Somatotrophs
The most frequent somatic change in somatotroph PitNETs is the heterozygous gain-of-function mutation of the
GNAS gene. The mutation to the G-protein subunit negatively affects GTPase activity, increases cAMP production, ultimately resulting in increased cell proliferation.
GNAS is an imprinted gene and any somatotroph PitNET
with a GNAS mutation will be located on the maternal allele. GNAS mutations are found in 30–40% of somatotroph
PitNETs and are clinically relevant because they may increase the sensitivity to somatostatin therapies. Song et al.
[29] reported that GNAS-mutated somatotrophs correlated
with being less invasive and less resistant to somatostatin
analogs. Similarly, GNAS-mutated tumors also had an increased expression of Dopamine Receptor 2 (DRD2); the
impact of the DRD2 is well-known from their high prevalence in lactotrophs, where it is thought to explain why lactotrophs are so responsive to dopamine agonists. However,
the relationship between increased dopamine receptor expression and responsiveness to dopamine agonists has not
been established yet in somatotrophs [32]. Interestingly,
the gonadotroph transcription factor SF-1 has been found
to be expressed in GNAS-wild type somatotrophs [22]. Somatotrophs have also been shown to have increased SSTR5
and SSTR2 expression in comparison to other SST receptors, which impacts their response to somatostatin analogs
(SSA) [33,34]. SSAs mainly target SSTR2 and SSTR5 and
have shown promising results. First-generation SSAs, octreotide and lanreotide, preferentially bind SSTR2 and have
moderate affinity for SSTR5. The newer SSA, pasireotide,
has greater binding affinity for SSTR5 and less for the rest
(SSTR2 > SSTR1 > SSTR3). The resistance to SSAs is
also influenced by GNAS imprinting [35]. PitNETs with relaxed GNAS imprinting had lower expression of GNAS and
SSTR expression, resulting in lower sensitivity to analogs
and therefore more aggressive behavior.
DNA hypomethylation of GH1 and SSTR5 is seen in
GH-secreting tumors. Song et al. [29] sequenced 125 ade6

nomas and found recurring mutations of GNAS in somatotrophs. Also, Song et al. [29] found additional recurring
loss-of-function mutations in MEN1 in plurihormonal adenomas producing both GH and PRL from patients without
a history of familial MEN1 syndrome or without germline
mutations of MEN1. Lastly, alterations of chromosome 1,
2, 11 and 18 positively correlated with tumor recurrence.
4.5 Thyrotrophs
Thyrotroph PitNETs account for 0.5–3% of all PitNETs [32]. Most of these tumors are sporadic and produce
TSH, leading to a clinical presentation consistent with central hyperthyroidism. The most common transcription factors involved in this tumor subtype are the PIT-1, GATA2/3, β-TSH, and/or a-subunit (a-SU). They also express
SSTR1, SSTR2, SSTR3, and SSTR5. Additionally, Luo et
al. [32] suggest the involvement of Wnt4 gene in tumorigenesis, as evidenced by the increased Wnt4 gene expression
seen in TSH PitNETs.
Thyrotroph tumors are often composed of fascicles of
spindle cells and can contain calcification and fibrous connective tissue. Basic fibroblast growth factor (bFGF) is involved in regulation of TSH and mediates the process of
fibrosis, which may explain why 40% of thyrotroph tumors
are more fibrotic than the rest of the PitNETs subtypes.
TSH-secreting PitNETs also include poorlydifferentiated PIT-1 tumors, previously known as silent
subtype 3. These are more aggressive and invasive tumors;
they express PIT-1, GATA-2/3, ER-α, a-SU, TSHb, GH,
PRL, and/or CAM5.2 and do not have a consistent hormone
expression pattern. Furthermore, TSH can be secreted in
conjunction with GH and PRL as part of a plurihormonal
PitNET. More specifically, co-secretion with GH and PRL
is seen in 16% and 10% of TSH PitNETs respectively.
Co-secretion with the rest of the hormones is very rare.
While surgery is the first line treatment for thyrotroph
tumors, somatostatin analogues can be effective against
some TSH-secreting tumors given their SSTR expression.
Unfortunately, poorly-differentiated PIT-1 tumors are resistant to medical therapy. Thyrotroph cells also express
dopamine receptors on their cell membrane, which is why
dopamine receptor agonists, such as bromocriptine and
cabergoline can be effective.
4.6 Lactotrophs
Lactotroph pituitary adenomas express mainly PRL
and arise from PIT-1 lineage of adenohypophyseal cells.
They are the most common functioning PitNETs, accounting for 30–50% of all adenomas. In addition to PIT-1,
lactotrophs also express ER-α. They are further subdivided into three subtypes: sparsely granulated lactotroph
adenomas (SGLA), densely granulated lactotroph adenomas (DGSA), and acidophil stem cell adenomas (ASCA).
SGLAs are the most common subtype and have an excellent response to treatment with a dopamine agonist. SGLAs

demonstrate Golgi-like PRL expression, while DGLAs and
ASCAs show expression diffusely in the cytoplasm. ASCAs will usually demonstrate scattered GH expression as
well diffuse PRL reactivity.
While lactotrophs can appear as part of a familial
syndrome such as MEN1, FIPA, or Carney complex, somatic mutations can occur in up to 19.8% of prolactinomas.
The most common mutation identified was in the splicing factor 3 subunit B1 (SF3B1), which results in stronger
binding of the pituitary-specific positive transcription factor 1, leading to abnormally elevated prolactin levels as
well as more rapid tumor growth. The presence of mutated SF3B1 portends worse prognosis for patients. Furthermore, lactotroph PitNETs demonstrated higher expression
of Dopamine receptor 2 (DRD2) which explains the effectiveness of dopamine agonists (e.g., cabergoline) as treatment and their adoption as the first-line agent. They also
express SSTR5, which is why SSA can influence prolactinomas. Given its affinity for SSTR5, pasireotide seems to
have the most effective SSA for this subtype.
Further multiomic research is necessary to elucidate
which lactotroph PitNETs are refractory to medical therapy. A study by Delgrange et al. [36] identified lactotroph
PitNETs in men as more likely to be treatment resistant
and demonstrate histopathological aggressiveness as compared to women, and are thus considered another high-risk
variant. As other studies have shown contradicting results
[37,38], further investigation utilizing multiomic analysis is
thereby needed.

5. Pathogenesis of familial PitNETs
Although most pituitary tumors are sporadic in nature,
5% of PitNETs are driven by monogenic germline mutations (Fig. 3). The familial subset of PitNETs can be divided
into isolated (only pituitary affected) and syndromic, such
as multiple endocrine neoplasia 1 and 4 (MEN1/4), neurofibromatosis type 1, and Carney complex. Familial isolated
pituitary adenoma (FIPA) and MEN1 account for most familial cases of pituitary adenoma. FIPA is characterized by
the presence of PitNETs in two or more family members
with no other syndromic features. Twenty percent of FIPA
patients are positive for a mutation in the Aryl hydrocarbon
receptor Interacting Protein (AIP) gene, which normally
regulates inflammatory pathways by stabilizing the aryl hydrocarbon receptor (AHR) in the cytoplasm; a widely distributed tumor suppressor protein expressed in GH cells and
PRL-secreting cells of the pituitary. The AIP mutation promotes somatotrophs and lactotrophs in patients in their 20s,
with 40% of patients presenting with gigantism, reflective
of its impact on younger patients. Another key characteristic is that AIP mutations predispose patients to more aggressive and large tumors with an increased risk for apoplexy,
that are poorly responsive to somatostatin analogues.
MEN1 patients typically present with the triad of a PitNET, primary hyperparathyroidism, and a pancreatic neu-

roendocrine tumor (i.e., gastrinoma) [33,34]. The MEN1
phenotype is inherited in an autosomal dominant fashion
with a germline mutation to the MEN1 gene located on chromosome 11, a ubiquitous transcription cofactor that normally regulates G1 -S cell cycle proteins, in turn serving
as a tumor suppressor. It encodes for the MENIN protein that is a scaffold protein and exerts its effect on cell
proliferation via histone methylation [33,34]. Patients with
MEN1 syndrome that do not present with a mutation to the
MEN1 gene often have mutations in CDKN1B; this phenotype is called the MEN4 syndrome. Correspondingly,
MEN1 pituitary-related disease usually presents with lactotrophs while MEN4 syndrome patients present with somatotroph PitNETs. Tumors that are MEN1 mutation carriers are more aggressive than MEN1-negative tumors.
Other familial syndromes, such as McCune-Albright
syndrome, Carney complex, and X-linked acrogigantism,
may result in either PitNETs or, less commonly, pituitary
hyperplasia [35]. McCune Albright syndrome is caused
by a missense mutation at Gln227 or Arg201 of the GNAS
gene during embryogenesis, leading to increased intracellular cAMP and subsequent hormonal dysregulation [39].
Because the mutation is acquired spontaneously during embryogenesis, the cells affected, and myriad symptoms are
distributed in a mosaic pattern. The typical triad of symptoms are ostotic fibrous dysplasia, café-au-lait spots, and
hyperfunctioning endocrinopathies, including acromegaly
in 20% of cases and hyperprolactinemia in 81% [40]. In a
review of all 112 patients with MAS and acromegaly, 54%
had a PitNET, and many of these tumors were exceptionally resistant to treatment. Surgery, which was attempted
in a minority of the patients, rarely cured GH/IGF-1 excess,
and medical treatment with somatostatin analogs achieved
control of acromegaly in only 30% of patients.
Carney complex is another multiple endocrine neoplasia that is most often inherited in an autosomal dominant
fashion [41]. Germline mutation of the PRKAR1A gene
on chromosome 17, responsible for 70% of familial cases,
leads to dysregulation of protein kinase A (PKA) activity
and tumor development in endocrine and non-endocrine organs. PKA is a cAMP-dependent threonine kinase that is involved in numerous intracellular signaling processes and its
role in each cell type is dependent on the substates present,
its localization within the cell, and the activity of regulatory
proteins [41]. Loss of function of PKA regulation, as seen
in the PRKAR1A mutation of Carney complex, results in
increased mitosis and cell proliferation in specific cells, including the somatotrophs of the anterior pituitary. In a study
of 353 patients, this mutation resulted in a GH-secreting PitNET in 12% of cases [42]. The PRKAR1A mutation also
drives development in 37% of non-familial cases of Carney complex, an even more rare occurrence [41]. Other
mutations in the protein kinase A regulatory subunit, such
as PRKACB, have been described [43]. Interestingly, the
acromegaly that results from Carney complex may be due
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Fig. 3. Familial syndromes or germline mutations associated with pituitary adenoma. AIP, aryl hydrocarbon receptorinteracting protein; CDKN1B, cyclin dependent kinase inhibitor 1B; FIPA, familial isolated pituitary adenoma; HPGL/PCC, hereditary
paraganglioma-pheochromocytoma; MAX, MYC Associated Factor X; MEN1/4, multiple endocrine neoplasia 1/4; NF1, neurofibromin
1; PRKAR1A, cAMP dependent protein kinase A (PKA) type I-α regulatory subunit (Riα); SDH, succinate dehydrogenase; TSC2,
tuberous sclerosis complex 2; USP8, ubiquitin specific peptidase 8. The asterisk (*) represents candidate genes for which additional data
are needed.

to a single GH-secreting tumor, multiple tumors, or hypersecretion of normal pituitary gland surrounding a tumor
[44]. For this reason, surgeons may need to pursue more aggressive resections, including sacrifice of the pituitary stalk,
in Carney complex patients to cure the acromegaly. Evidence from pediatric patients with Cushing’s disease also
identified CABLES1, a regulator in adrenal-pituitary negative feedback, as a novel pituitary tumor-predisposing gene
[45]. Lastly, screening in familial PA determined that 33%
of families harbored cadherin-related 23 (CDH23) variants
[46].
In X-linked acrogigantism (XLAG), a somatic or
germline duplication in the G protein-coupled receptor 1
(GPR101) gene leads to excess release of growth hormone
and gigantism in the pediatric population that it affects [47].
Patients can develop either hyperplasia or PitNET, with
8

the most common subtype being a somatotroph/lactotroph
mixed adenoma. Excess growth hormone and prolactin result in acceleration of linear growth early in life and hyperprolactinemia, respectively [47,48]. The duplication is
inherited in an X-linked dominant fashion, so females who
are heterozygous will also develop the pathology. Most often, XLAG arises from a de novo GPR101 duplication and
therefore only a single individual is affected; only three familial cases have been described [49]. Approximately 7.8
to 10% of patients with gigantism harbor this mutation [50].
Although PitNETs are often macroadenomas, they are less
likely to invade locally or cause pituitary apoplexy than do
the AIP-mutated somatotroph/lactotroph mixed macroadenomas [48]. While PitNETs should be treated with surgical
resection as first-line therapy, pituitary hyperplasia may be
controlled with GH receptor antagonist drugs [48,51].

Neurofibromatosis 1 is a syndrome characterized by
changes in skin pigmentation and development of nerve
sheath tumors. Its pathology is driven by a mutation in the
NF1 gene, which encodes for the tumor suppressor neurofibromin, and is either inherited in an autosomal dominant
manner or results from a de novo mutation. Although central nervous system tumors (e.g., optic gliomas) are common, pituitary adenomas are very rarely associated with
NF-1 but there does not appear to be a clear link between
the two [52]. Similarly, tuberous sclerosis and Lynch syndrome are two entities rarely associated with PitNETs, however, there is not a clear link to PitNET tumorigenesis. Further multiomic investigation is warranted to elucidate these
relationships.
The “three PAs” is a new term describing the association between PitNETs, pheochromocytomas, and
paragangliomas [53,54]. Although they may co-occur
by coincidence, growing evidence suggests classical
pheochromocytoma/paraganglioma-predisposing
genes
may also promote pituitary tumorigenesis. These tumor
cells are driven by a mutated form of succinate dehydrogenase, an enzyme critical for cellular energy production,
and mutations in any of the four genes encoding the
SDH subunits (SDHx; SDHA, SDHB, SDHC, SDHD) are
associated with the 3PAs [49,54]. Less frequently, other
genetic causes of this association have been implicated,
namely the MEN hereditary endocrine syndromes [55–58].
The PitNETs involved are commonly lactotrophs, somatotrophs, or non-functioning and represent more aggressive
and treatment resistant tumors [58]. In a comprehensive
review of patients with both PitNETs and pheochromocytoma/paraganglioma, the genetic screening was limited
with nearly half of the patients not undergoing any testing,
highlighting the need for comprehensive genome-wide
analysis to ascertain association/causality [54].

6. Conclusions
The increased reliance on transcription factor characterization of PitNETs will likely add to current hormonal
immunostaining and continue to be refined. Developing
a better understanding of PitNET multiomics will be instrumental in improving our management of PitNETs that
are refractory to our current gold-standard treatments. The
multiomic approach will allow better patient classification,
and prediction of prognosis.
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